Dilworth JR, Lewis JS, Miller JR, Zheng Y. The preparation of rhenium (V) oxo- and imido- complexes with Et2NCSNCOPh and Et2NCSNC(NH)Ph. The crystal and molecular structure of [ReOCl(PhCONCSEt2)2]. Polyhedron 12:221-225, 1993.
Dilworth JR, Lewis JS, Miller JR, Zheng Y. Rhenium complex of a triply deprotonated chelated thiosemicarbazide and its conversion to a nitride complex via a hydrazide intermediate. Crystal structure of [ReCI2(NH)(NHNH2)(PPh3)2]. Journal of the Chemical Society, Dalton Transactions, 1357-1361, 1995.
Dilworth JR, Hutson AJ, Lewis JS, Miller JR, Zheng Y, Chen Q, Zubieta J. Complexes of potentially tri- and tetradentate phosphinothiol ligands with Mo, W, Re, Fe, Ru, Os, Rh, Ir and Ni. The crystal and molecular structures of [Me4N]2[Mo(CO)3{PhP(C6H4-2S)2}], [Re{PhP(C6H4-2S)2}2] and [IrH(CO){PhP(C6H4-2S)2}(PPh3)]. Journal of the Chemical Society, Dalton Transactions, 1093-1104, 1996.
Lewis JS, Zweit J, Dearling JLJ, Rooney BC, Blower PJ. Copper(I)bisphosphine complexes as a basis for radiopharmaceuticals for positron emission tomography and targeted radiotherapy. Chemical Communications, 1093-1094, 1996.
Blower PJ, Lewis JS, Zweit J. Copper Radionuclides and Radiopharmaceuticals in Nuclear Medicine. Nuclear Medicine and Biology 23: 957-980, 1996.
Lewis JS, Heath SL, Powell AK, Zweit J, Blower PJ. Diphosphine bifunctional chelators for low-valent metal ions. Crystal structures of the copper(I) complexes [CuClL12] and [CuL12][PF6] [L1 = 2,3-bis(diphenylphosphino)maleic anhydride]. Journal of the Chemical Society, Dalton Trans, 855-863, 1997.
Lewis JS, Zweit J, Blower PJ. Effect of ligand and solvent on chloride ion coordination in anti-tumour copper(I) diphosphine complexes: synthesis of [Cu(dppe)2]Cl and analogous complexes (dppe = 1,2-bis(diphenylphosphino)ethane). Polyhedron 17:513-517, 1998.
Anderson CJ, Jones LA, Bass LA, Sherman ELC, McCarthy DW, Cutler PD, Lanahan MV, Cristel ME, Lewis JS, Schwarz SW. Radiotherapy, toxicity and dosimetry of copper-64-labeled-TETA-octreotide in tumor bearing rats. Journal of Nuclear Medicine 39:1944-1951, 1998.
Dearling JLJ, Lewis JS, Mullen GED, Rae MT, Zweit J, Blower PJ. Design of hypoxia targeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro. European Journal of Nuclear Medicine 25:788-792, 1998.
Dearling JLJ, Lewis JS, McCarthy DW, Welch MJ, Blower PJ. Redox-active metal complexes for imaging hypoxic tissues: structure-activity relationships in copper(II) bis(thiosemicarbazone) complexes. Chemical Communications 22:2531-2533, 1998.
Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. The evaluation of 64Cu-diacetyl-bis(N4-methylthiosemicarbazone)(64Cu-ATSM) In vitro and in vivo in a hypoxic tumor model. Journal of Nuclear Medicine 40:177-183, 1999.
Dearling JLJ, Mullen GED, Lewis JS, Rae MR, Zweit J, Welch MJ and Blower PJ. Hypoxia-Selective Copper-64 Complexes. In: Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 5, Eds: M. Nicolini and U. Mazzi, 599-605, 1999.
Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Anderson CJ. Structure-activity studies of Cu-64-labeled somatostatin analogs for diagnostic imaging and targeted radiotherapy. In: Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 5, Eds: M. Nicolini and U. Mazzi, 53-59, 1999.
Lewis JS, Srinivasan A, Schmidt MA, Anderson CJ. In vitro and in vivo evaluation of copper-64-TETA-Tyr3-octreotate: A new somatostatin analog with improved tissue target uptake. Nuclear Medicine and Biology 26:267-273, 1999.
Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. Journal of Medicinal Chemistry 42:1341-1347, 1999.
Reichert DE, Lewis JS, Anderson CJ. Metal Complexes as Diagnostic Tools. Coordination Chemistry Reviews 184:3-66, 1999.
Cutler CS, Lewis JS, Anderson CJ. Utilization of Metabolic, Transport and Receptor-Mediated Processes to Deliver Agents for Cancer Diagnosis. Advanced Drug Delivery Reviews 37:189-212, 1999.
Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, Morris MM, Miller JP and Anderson CJ. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive tumor-bearing rat model. Clinical Cancer Research 5:3608-3616, 1999
Lewis JS, Dearling JLJ, Sosabowski, Zweit J, Carnochan P, Kelland LR, Coley HM, Blower PJ. Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumors by positron emission tomography. European Journal of Nuclear Medicine 27:638-646, 2000.
Anderson CJ, Lewis JS. Radiopharmaceuticals for targeted radiotherapy of cancer. Expert Opinion on Therapeutic Patents 10(7): 1057-1069, 2000.
Lewis JS, Laforest R, Lewis MR, Anderson CJ. Comparative dosimetry of copper-64 and yttrium-90-Labeled somatostatin analogs in a tumor-bearing rat model. Cancer Biotherapy & Radiopharmaceuticals 15(6):593-604, 2000.
Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW. Copper-64-TETA-Octreotide as a PET imaging agent for patients with neuroendocrine tumors. Journal of Nuclear Medicine, 42:213-221, 2001.
Lewis JS, Laforest R, Buettner TL, Song S-K, Fujibayashi Y, Connett JM and Welch MJ. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy. Proceedings of the National Academy of Sciences, 98(3):1206-1211, 2001.
Chao KSC, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity modulated radiation therapy. International Journal of Radiation Oncology, Biology, and Physics, 49(2):1171-1182, 2001.
Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-64-diacetyl-bis(N4-methylthiosemicarbazone): Effect of changes in tissue oxygenation. Journal of Nuclear Medicine, 42:655-661, 2001.
Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-64-diacetyl-bis(N4-methylthiosemicarbazone): Effect of changes in tissue oxygenation. Journal of Nuclear Medicine, 42:655-661, 2001.
Lewis JS, Welch MJ. PET imaging of hypoxia. Quarterly Journal of Nuclear Medicine, 45(2): 183-188, 2001.
Lewis JS, Wang M, Laforest R, Wang F, Erion JL, Bugaj JE, Srinivasan A, Anderson CJ. Toxicity and dosimetry of 177Lu-DOTA-Y3-octreotate in a rat model. International Journal of Cancer, 94: 873-877, 2001.
Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone)(Cu-ATSM) in tumor cells. Annals of Nuclear Medicine, 15(6):499-504, 2001.
Lewis JS, Connett JM, Garbow JR, Buettner TL, Fujibayashi Y, Fleshman JW, Welch MJ Copper-64-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for the Prevention of Tumor Growth at Wound Sites following Laparoscopic Surgery: Monitoring Therapy Response with microPET and Magnetic Resonance Imaging. Cancer Research, 62: 445-449, 2002.
Dearling JLJ, Lewis JS, Mullen GED, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. Journal of Biological Inorganic Chemistry, 7: 249-259, 2002.
Li WP, Lewis JS, Kim JY, Bugaj JE, Johnson MA, Erion JL, Anderson CJ. DOTA-D-Tyr1-Octreotate: A Somatostatin Analogue for Labeling with Metal and Halogen Radionuclides for Cancer Imaging and Therapy. Bioconjugate Chemistry, 13(4):721-728, 2002.
Lewis JS, Achilefu S, Garbow JR, Laforest R, Welch MJ. Small Animal Imaging: Current Technology and Perspectives for Oncological Imaging. European Journal of Cancer, 38:2173-2188, 2002.
Lewis JS, Herrero P, Sharp TL, Engelbach JA, Fujibayashi Y, Laforest R, Kovacs A, Gropler RJ, Welch MJ. Delineation of Hypoxia in Canine Myocardium using PET and Copper-diacetyl-bis(N4-methylthiosemicarbazone). Journal of Nuclear Medicine, 43:1557-1569, 2002.
Vavere A. L., Lewis JS and Welch MJ. Imaging of Antiangiogenic Treatments: Ti-45-transferrin MicroPET as a Surrogate Marker for Tumor Response. In: Technetium, Rhenium and other Metals in Chemistry and Nuclear Medicine 6, Eds: M. Nicolini and U. Mazzi, 101-105, 2002.
Lewis JS and Welch MJ. Copper chemistry related to radiopharmaceutical production. In: Technetium, Rhenium and other Metals in Chemistry and Nuclear Medicine 6, Eds: M. Nicolini and U. Mazzi, 23-33, 2002.
Zalutsky MR, Lewis JS. Radiolabeled antibodies for tumor imaging and therapy, In Handbook of Radiopharmaceuticals: Radiochemistry and Applications. Eds: M. J. Welch and C. S. Redvanly 685-714, 2002.
Rowland DJ, Lewis JS, Welch MJ. Molecular Imaging: The Application of Small Animal Positron Emission Tomography. Journal of Cellular Biochemistry, Suppl 39:110-115, 2002.
Dehdashti F, Grigsby RW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing Tumor Hypoxia in Cervical Cancer by Positron Emission Tomography with 60Cu-ATSM: Relationship to Therapeutic Response - A Preliminary Report. International Journal of Radiation Oncology, Biology, and Physics, 55(5):1233-1238, 2003.
Scappaticci FA, Conteras A, Boswell CA, Lewis JS, and Nolan G. Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice. Vaccine, 21:2667-2666, 2003.
Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA. In Vivo Assessment of Tumor Hypoxia in Lung Cancer with 60Cu-ATSM. European Journal of Nuclear Medicine and Molecular Imaging, 30: 844-850, 2003.
Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, Furukawa T, Lewis JS, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y. Intra-tumoral distribution of 64Cu-ATSM: A comparison study with FDG. Nuclear Medicine and Biology 30:529-534, 2003.
Welch MJ and Lewis JS. [Tc(CO) 3]+ chemistry: a promising new concept for SPECT? European Journal of Nuclear Medicine and Molecular Imaging 30(9); 1302-1304, 2003.
Mathias CJ, Lewis MR, Reichert DE, Laforest R, Sharp TL, Lewis JS, Yang Z-F, Waters DJ, Snyder PW,Low PS, Welch MJ and Green MA. Preparation of 66Ga- and 68Ga-labeled Ga(III)-Deferoxamine-Folate as Potential Folate-Receptor-Targeted PET Radiopharmaceuticals. Nuclear Medicine and Biology, 30:725-731, 2003.
Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ. Enhancing Targeted Radiotherapy by 64Cu-ATSM using 2-Deoxy-D-Glucose. Cancer Research, 63:5496-5504, 2003.
Vavere AL, and Lewis JS. Imaging the Effects of Anti-Angiogenic Treatments, Quarterly Journal Nuclear Medicine, 47(3); 163-170, 2003.
McQuade, Rowland D, Lewis JS, Welch MJ. Positron-Emitting Isotopes Produced on Biomedical Cyclotrons. Current Medicinal Chemistry, 12, 71-88, 2005.
Obato A, Kasmatsu S, Lewis JS, Furukawa T, Takamatsu S, Toyahara J, Asai T, Welch MJ, Adams SG, Saji H, Yonekura Y, Fujibayashi Y. Basic characterization of 64Cu-ATSM as a radiotherapy agent. Nuclear Medicine and Biology, 32:21-28, 2005.
McQuade P, Martin KE, Castle TC, Went MJ, Blower PJ, Welch MJ, Lewis JS. Investigation into 64Cu labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as Hypoxia Imaging Agents. Nuclear Medicine and Biology 32, 147-156, 2005.
O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL. Assessment of Regional Tumor Hypoxia using 18F-FMISO and 64Cu-ATSM Positron Emission Tomography: A Comparative Study featuring MicroPET Imaging, pO2 Probe Measurement, Autoradiography and Fluorescent Microscopy in the R3327-AT and FaDu Rat Tumor Models. International Journal of Radiation Oncology, Biology, and Physics, 61(5): 1493-1502, 2005.
McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using 64Cu and 86Y-DOTA-ReCCSMH(Arg11), a cyclized peptide analog of á-MSH. Journal of Medicinal Chemistry. 48, 2985-2992, 2005.
Viehl CT, Becker-Hapak M, Lewis JS, Tanak Y, Liyanage UK, Linehan DC, Eberlein TJ, Goedegebuure PS. A Tat Fusion Protein-Based Tumor Vaccine for Breast Cancer. Annals of Surgical Oncology. 12(7): 517-525, 2005.
Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line dependent differences in uptake and retention of the hypoxia selective nuclear imaging agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM). Nuclear Medicine and Biology, 32(6):623-630, 2005.
Laforest R, Dehdashti F, Lewis JS, Schwarz SW. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. European Journal of Nuclear Medicine and Molecular Imaging 32:764-770, 2005.
Parry R, Schneider D, Hudson D, Parkes D, Xuan J-A, Newton A, Toy P, Lin R, Harkins R, Alicke B, Biroc S, Kretschmer PJ, Halks-Miller M, Klocker H, Zhu Y, Larsen B, Cobb RR, Bringmann P, Roth G, Lewis JS, Dinter H, Parry G. Identification of a Novel Prostate Tumor Target, Mindin/RG-1, for Antibody-Based Radiotherapy of Prostate Cancer. Cancer Research 65, 8397-8405, 2005.
Laforest R, Sharp TL, Engelbach JA, Fettig NM, Herrero P, Kim J, Lewis JS, Rowland DJ, Tai Y-C, Welch MJ. Measurement of Input Functions in Rodents: Challenges and Solutions. Nuclear Medicine and Biology 32: 679-685, 2005.
Yoo J, Tang L, Perkins TA, Rowland DJ, Laforest R, Lewis JS, Welch MJ. Preparation of High Specific Activity 86Y Using a Small Biomedical Cyclotron. Nuclear Medicine and Biology, 32: 891-897, 2005.
Kim J, Herrero P, Sharp TL, Laforest R, Rowland DJ, Tai Y-C, Lewis JS, Welch MJ. A Minimally Invasive Method of Determining Blood Input Function from PET Images in Rodents. Journal of Nuclear Medicine, 47:330-336, 2006.
Herrero P, Kim J, Sharp TL, Engelbach JA, Lewis JS, Gropler RJ, Welch MJ. Assessment of myocardial blood flow using 15O-water and 1-[11C]-acetate in rats with small animal PET. Journal of Nuclear Medicine, 47:477-485, 2006.
Ruangma A, Bai B, Lewis JS, Sun X, Welch MJ, Leahy R, Laforest R. Imaging with 3-D Maximum a posteriori (MAP) with Radiopharmaceuticals Labeled with Three Copper Radionuclides. Nuclear Medicine and Biology, 33: 217-226, 2006.
Welch MJ, Lewis JS, Kim J, Sharp TL, Dence CS, Gropler RJ, Herrero P. Assessment of myocardial metabolism in diabetic rats utilizing small animal PET imaging: A feasibility study. Journal of Nuclear Medicine, 47: 689-697, 2006.
Silva MJ, Uthgenannt BA, Rutlin JR, Wohl GR, Lewis JS, Welch MJ. In vivo skeletal imaging of 18F-fluoride with positron emission tomography reveals damage- and time-dependent responses to fatigue loading in the rat ulna. Bone, 39: 229-236, 2006.
Clifford T, Boswell CA, Biddlecombe GB, Lewis JS, Brechbiel MW. Validation of a Novel CHX-A” Derivative Suitable for Peptide Conjugation: Small Animal PET/CT Imaging using Yttrium-86-CHX-A”-Octreotide, Journal of Medicinal Chemistry, 49: 4297-4304, 2006
Welch MJ, Laforest R, Lewis JS. Production of Non-Standard PET Radionuclides and the Application of Radiopharmaceuticals Labeled with these Nuclides, in PET Chemistry: The Driving Force in Molecular Imaging Series: Ernst Schering Research Foundation Workshop, Vol. 62. Schubiger, P. August; Lehmann, Lutz; Friebe, Matthias (Eds.), XII, 159-182, 2007.
Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KSC, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D. Hypoxia: Importance in Tumor Biology, Noninvasive Measurement by Imaging, and Value of its Measurement in the Management of Cancer Therapy. (Proceedings of an NIC workshop “Hypoxia: Importance in Tumor Biology, Noninvasive Measurement by Imaging, and Value of its Measurement in the Management of Cancer Therapy,” April 5-6, 2004, in Phoenix). International Journal of Radiation Biology, 82, 699-757, 2006.
Wei L, Easmon J, Nagi RK, Muegge BD, Meyer LA, Lewis JS. 64Cu-azabicyclo[3.2.2]nonane Thiosemicarbazone Complexes: Radiopharmaceuticals for the PET Imaging of Topoisomerase-II Expression in Tumors. Journal of Nuclear Medicine, 47: 2034-2041, 2006.
Wei L, Butcher C, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Lewis JS. Synthesis and Biological Evaluation of Cu-64 labeled Rhenium-Cyclized alpha-MSH Peptide Analog Using a Cross-Bridged Cyclam Chelator. Journal of Nuclear Medicine 48: 64-72, 2007.
Jost SC, Wanebo JE, Song SK, Chicoine MR, Rich KM, Woolsey TA, Lewis JS, Mach RH, Xu J, Garbow JR. In Vivo Imaging in a Murine Model of Glioblastoma, Neurosurgery, 60, 360-370, 2007.
Padhani A, Krohn KA, Lewis JS, Alber M. Imaging Oxygenation of Human Tumours. European Radiology, 17, 861-872, 2007.
Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, Lewis JS. Molecular Imaging of Gastrin-Releasing Peptide Receptor-Positive Tumors in Mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-Bombesin(1-14). Bioconjugate Chemistry, 18, 724-730, 2007.
Lewis JS, Anderson CJ. Radiometal-labeled somatostatin analogues for applications in cancer imaging and therapy. In Peptide Characterization and Application Protocols (Methods in Molecular Biology, 386), G.B. Fields (Ed), Humana Press, ISBN 1-588-29550-8, Chapter 8, 227-240, 2007.
Vâvere AL, and Lewis JS. Cu-ATSM: A radiopharmaceutical for the PET imaging of hypoxia, Dalton Trans. 43, 4893-4902, 2007.
Wei L, Miao Y, Gallazzi F, Quinn T, Welch M, V¨¡vere AL, Lewis JS. Ga-68 labeled DOTA-rhenium cyclized ¦Á-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nuclear Medicine and Biology, 34:945-953, 2007
Vâvere AL, Kridel SJ, Wheeler FB, Lewis JS. 1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer. Journal of Nuclear Medicine, 49:327-334, 2008.
Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone) Journal of Nuclear Medicine, 49:201-205, 2008.
Alidori S, Gioia Lobbia G, Papini G, Pellei M, Porchia M, Refosco F, Tisato F, Lewis JS, Santini C. Synthesis, in vitro and in vivo characterization of 64Cu(I)-complexes derived from hydrophilic tris(hydroxymethyl)phosphane and 1,3,5-triaza-7-phosphaadamantane ligands. Journal of Biological Inorganic Chemistry, 13:307-315, 2008.
Lewis JS, Welch MJ and Tang L. Workshop on the Production, application and clinical translation of 'non-standard' PET nuclides: a meeting report. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 52, 101-106, 2008.
Vâvere AL, Lewis JS. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. Nuclear Medicine and Biology, 35, 273-279, 2008.
Bonnitcha PD, Vâvere AL, Lewis JS, Dilworth JR. In vitro and in vivo evaluation of bifunctional bisthiosemicarbazone 64Cu-complexes for the positron emission tomography imaging of hypoxia. Journal of Medicinal Chemistry, 51 2985-2991, 2008.
Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An Imaging Comparison of 64Cu-ATSM and 60Cu-ATSM in Cancer of the Uterine Cervix. Journal of Nuclear Medicine, 49:1177-1182, 2008.
Zhou D, Sharp TL, Fettig NM, Lee H, Lewis JS, Katzenellenbogen JA, Welch MJ. Evaluation of a Bromine-76 Labeled Progestin 16alpha,17alpha-dioxolane for Breast Tumor Imaging and Radiotherapy: in vivo Biodistribution and Metabolic Stability Studies. Nuclear Medicine and Biology, 35: 655-63, 2008
Dietz D W, Dehdashti FD, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch M J, Siegel B A. Tumor hypoxia detected by Positron Emission Tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Diseases of the Colon & Rectum, 51; 1641-1648, 2008.
Dence CS, Ponde DE, Welch MJ, Lewis JS. Autoradiographic and Small-Animal PET Comparisons Between 18F-FMISO, 18F-FDG, 18F-FLT and the Hypoxic Selective 64Cu-ATSM in a Rodent Model of Cancer, Nuclear Medicine and Biology, 35:713-20, 2008
Papini G, Alidori S, Lewis JS, Reichert DE, Pellei M, Gioia Lobbia G, Biddlecombe GB, Anderson CJ, Santini C. Synthesis and Characterization of the Copper(II) Complexes of New N2S2-donor Macrocyclic Ligands: Synthesis and In Vivo Evaluation of the 64Cu Complexes. Dalton Transactions, 1:177-184, 2009, 2009.
Wei L, Ye Y, Wadas T, Lewis JS, Welch MJ, Achilefu S, Anderson CJ. 64Cu-Labeled CB-TE2A and DiamSar Conjugated RGD Peptide Analogs for Targeting Angiogenesis: Comparison of their Biological Activity, Nuclear Medicine and Biology, 36, 227-285, 2009.
Schneider DW, Heitner T, Alicke B, Light DR, McLean K, Satozawa N, Parry G, Yoo J, Lewis JS, Parry R. In vivo biodistribution, PET imaging and tumor accumulation of [86Y] and [111In] anti-mindin/RG-1, engineered antibody fragments (scFv, diabody and IgE-CH4 miniantibody) in LNCaP tumor-bearing nude mice. Journal of Nuclear Medicine, 50, 435-443, 2009.
Wei L, Zhang X, Gallazzi F, Miao Y, Jin X, Brechbiel MW, Xu H, Clifford T, Welch MJ, Lewis JS, Quinn TP. Melanoma Imaging using 111In, 86Y and 68Ga labeled CHX-A''-Re(Arg11)CCMSH. Nuclear Medicine and Biology, 36, 345-354, 2009.
Dong Z, Haibing Z, Jenks, C, Lewis JS, Katzenellenbogen J, Welch MJ. Bromination from the Macroscopic Level to the Tracer Radiochemical Level: 76Br Radiolabeling of Aromatic Compounds via Electrophilic Substitution. Bioconjugate Chem, 20, 818-806, 2009
Holland JP, Lewis JS, Dehdashti F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Quaterly Journal of Nuclear Medicine and Molecular Imaging. 53,193-200, 2009.
Holland JP, Jones MW, Bonnitcha PD, Lewis JS, Dilworth JR. Functionalised copper-64 complexes as precursors of potential PET imaging agents for neurodegenerative disorders. New Journal of Chemistry, 33, 1845-1852, 2009
Dunphy MP. Lewis JS. Radiopharmaceuticals in Pre-Clinical and Clinical Development for Therapy Monitoring with PET. Journal of Nuclear Medicine, 50, 106S-121S, 2009.
Vâvere AL, Biddlecombe GB, Spees WM, Garbow JR, Wijesinghe D, Andreev OA, Engelman DM, Reshetnyak YK, Lewis JS. A Novel Technology for the Imaging of Acidic Prostate Tumors by Positron Emission Tomography. Cancer Research, 69, 4510-4516, 2009
Holland JP, Ferdani R, Anderson CJ, Lewis JS. Copper-64-Radiopharmaceticals for Oncologic Imaging. PET Clinics 4, 49-67, 2009
Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nuclear Medicine & Biology, 2009, 729-739, 2009.
Bonnitcha PD, Bayly SR, Theobald MBM, Betts HM, Lewis JS, Dilworth JR. Nitroimidazole Conjugates of Bis(thiosemicarbazonato)64Cu(II) - Potential Combination Agents for the PET Imaging of Hypoxia. Journal of Inorganic Biochemistry, 102, 126-135, 2010
Holland JP, Caldos-Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, Chiosis G, Lewis JS. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr-DFO-trastuzumab, PLoS One, 5(1), e8859, 2010
Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol. Imaging, 9, 1-20, 2010.
Anderson H, Pillarsetty N, Cantorias M, Lewis JS. Improved synthesis of 2'-deoxy-2'-[18F]-fluoro-1-beta-D-arabinofuranosyl-5-iodouracil ([18F]-FIAU). Nucl Med Biol, 37, 439-442, 2010.
Zeglis BM, Holland JP, Lebedev AY, Cantorias MV, Lewis JS. Radiopharmaceuticals for Imaging in Oncology. Chapter 2 in Nuclear Oncology: Basic Principles and Clinical Applications, Eds. Strauss HW & Mariani G., Springer. In press, 2010
Lebedev AY, Holland JP, Lewis JS. Clickable bifunctional radiometal chelates for peptide radiolabeling, Chem. Commun., 46, 1706-1708, 2010.
Ruggiero A, Holland JP, Lewis JS and Grimm J. Cerenkov luminescence imaging of medical isotopes, J Nucl Med, 51(7):1123-30, 2010.
Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET imaging of prostate-specific membrane antigen (PSMA) expression in vivo. J Nucl Med 51(8):1293-300, 2010.
Holland JP, Normand G, Riggiero A, Lewis JS, Grimm J. Intra-operative imaging of PET radiotracers using Cerenkov luminescence emissions. Molecular Imaging, in press, 2011.
Ruggiero A, Villa CH, Holland JP, Sprinkle SR, May C, Lewis JS, Scheinberg DA, McDevitt MR. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. International Journal of Nanomedicine. 5, 783-802, 2010.
Dunphy PS, Zanzonico P, Veach D, Null M, Somwar R, Pillarsetty N, Lewis JS, Larson SM. Dosimetry of 18F-Labeled Tyrosine Kinase Inhibitor SKI-249380, a Dasatinib-Tracer for PET Imaging. Molecular Imaging & Biology, in press, 2011
Zeglis BM, Pillarsetty N, Divilov V, Blasberg¬ RA, Lewis JS. The Synthesis and Evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N¬8-hydroxyoctanediamide ([18F]-FESAHA), A PET Radiotracer Designed for the Delineation of Histone Deacetylase Expression in Cancer. Nucl Med Biol, in press, 2011.
Heneweer C, Holland JP, Divilov V, Carlin S, Lewis JS. Magnitude of enhanced permeability and retention (EPR) effect in tumors with different phenotypes - 89Zr-albumin as a model system, J Nucl Med, in press,52(4), 625-33, 2011.
Zeglis BM, Divilo V, Lewis JS. The Role of Metallation in the Topoisomerase II-alpha Inhibition and Anti-Proliferation Activity of a Series of alpha-Heterocyclic-4N-Substituted Thiosemicarbazones and their Cu(II) Complexes. J Med Chem,54(7), 2391-8, 2011
Zeglis BM and Lewis JS. A Practical Guide to the Construction of Radiometallated Bioconjugates for Positron Emission Tomography. Dalton Trans, in press, 2011
